Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
Date:2/28/2011

denix has follow-on drug candidates in the protease inhibitor class that are currently in preclinical development. Idenix anticipates selecting a clinical candidate with broad genotypic activity in 2011.

HCV Nucleoside/tides and ProdrugsIdenix is committed to an intensive and renewed strategy in the discovery and development of nucleoside/tides, with potential application against HCV and other infectious diseases. Currently, Idenix is pursuing multiple follow-on and novel nucleoside/tide programs.

GSK2248761, known as '761 (formerly IDX899), an HIV NNRTI In February 2011, Idenix was informed by ViiV Healthcare Company (ViiV) that '761 was placed on clinical hold by the FDA. ViiV has full responsibility for the development of '761, including any regulatory interactions.

"We are very pleased that the FDA has allowed IDX184, our lead HCV nucleoside inhibitor drug candidate, to advance directly into clinical trials," said Ron Renaud, President and CEO. "We gained insights about our most advanced clinical drug candidates as we prepared our response to the FDA clinical hold, and can apply this knowledge to ongoing preclinical programs. We are excited about our renewed focus on our nucleoside capabilities, as well as multiple opportunities to develop diverse direct-acting antiviral drug candidate classes for HCV."

Fourth Quarter and Full Year 2010 Financial ResultsFor the fourth quarter ended December 31, 2010, Idenix reported total revenues of $2.4 million, compared to total revenues of $3.0 million in the fourth quarter of 2009. The company reported a net loss of $16.2 million, or a loss of $0.22 per basic and diluted share, for the fourth quarter ended December 31, 2010, compared to a net loss of $12.3 million, or a loss of $0.19 per basic and diluted share for the fourth quarter ended December 31, 2009.

For the twelve months ended December 31, 2010, Idenix reported total revenues of $10.2 million, compared to total revenue
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals to Hold an Investor/Analyst Day Event on October 30, 2010
2. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
5. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
8. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
9. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
10. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
11. Idenix Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Niagara Thermal Products is proud to announce that ... ("B3") as the critical thermal component supplier in support ... Corps of Engineers.  B3 has developed the only comprehensive ... destroys VOCs and other chemical pollutants, allergens and organic ...
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... 17, 2012 The " Anesthesia Drugs ... analyzes and studies the U.S. market for intravenous anesthesia drugs with ... buyers, export & import system for controlled substances in U.S. and U.S. ... in-depth TOC of   " Anesthesia Drugs ...
... clinical trial, a paralyzed woman was able to reach for and ... time in nearly 15 years by using her thoughts to ... the National Institutes of Health, is evaluating the safety and feasibility ... This is a type of brain-computer interface (BCI) intended to put ...
... 2012  Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) ... the Company,s common share repurchase program authorization by an ... of 2008, the Company has returned $236 million to ... and preferred shares, representing approximately 27% of its shares ...
Cached Biology Technology:Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 2Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 2Paralyzed individuals use thought-controlled robotic arm to reach and grasp 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 4Paralyzed individuals use thought-controlled robotic arm to reach and grasp 5Questcor Pharmaceuticals Expands Repurchase Program 2Questcor Pharmaceuticals Expands Repurchase Program 3Questcor Pharmaceuticals Expands Repurchase Program 4Questcor Pharmaceuticals Expands Repurchase Program 5
(Date:4/24/2014)... puts out a welcome mat to bacteria seeking to invade, ... study published this week in the Proceedings of the ... battle between microbe and host that researchers can exploit to ... oft-studied plant Arabidopsis puts out a molecular signal ... a hostile army were unknowingly passing by a castle, and ...
(Date:4/23/2014)... chronic inflammatory disorders among people of lower socioeconomic status ... to the microbes that thrive in rural environments, according ... in the journal Clinical & Experimental Immunology , ... less access to green spaces may be more apt ... system dysfunction. , When our immune systems are working ...
(Date:4/23/2014)... new study from the Indiana University School of Public ... and heart disease by finding a strong association between ... coronary heart disease. , The study found that heme ... by 57 percent, while no association was found between ... sources, and coronary heart disease. , The study was ...
Breaking Biology News(10 mins):How a plant beckons the bacteria that will do it harm 2How a plant beckons the bacteria that will do it harm 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3Study: Iron consumption can increase risk for heart disease 2
... Researchers have identified genetic markers that may influence whether ... according to a national longitudinal study of thousands of young ... Developmental Psychology , a publication of the American Psychological Association. ... related in any way to academic achievement is a big ...
... laparoscopic surgery "minimally invasive" instruments enter the patient through ... work on different tasks, surgeons all see the same view. ... suited to the specific task? In a new paper, pediatric ... Brown University and Hasbro Children,s Hospital report that in a ...
... Cancer Center have uncovered a single molecule they say ... used to treat or prevent breast cancer in high-risk ... Cancer Research , the scientists say glucose-regulated protein 78 ... the agents tamoxifen and fulvestrant, turns off apoptosis, a ...
Cached Biology News:Genes may play role in educational achievement, study finds 2Individual perspectives improve laparoscopy 2Individual perspectives improve laparoscopy 3Single protein promotes resistance to widely used anti-estrogen drugs 2Single protein promotes resistance to widely used anti-estrogen drugs 3
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Rabbit polyclonal to M13 Bacteriophage Coat Proteins ( Abpromise for all tested applications)....
E2F-5...
Rabbit polyclonal to Flagellin ( Abpromise for all tested applications). Antigen: Synthetic peptide from the flagellin C terminal domain of Burkholderia pseudomallei....
Biology Products: